TY - JOUR T1 -欧洲囊性纤维化患者的生存估计及社会经济因素的影响:回顾性登记队列研究JF -欧洲呼吸杂志JO - Eur Respir J DO - 10.1183/13993003.02288-2020 SP - 2002288 AU - McKone, Edward F. AU - Ariti, Cono AU - Jackson, Abaigeal AU - Zolin, Anna AU - Carr, Siobhán B. AU - Orenti, Annalisa AU - van Rens, Jacqui AU - Lemonnier, Lydie AU - Macek, Milan AU - Keogh, Ruth H. AU - Naehrlich, Lutz A2 -，Y1 - 201/01/01 UR - //www.qdcxjkg.com/content/early/2021/02/11/13993003.02288-2020.abstract N2 -背景欧洲囊性纤维化(CF)患者的中位生存期未知，可能受到社会经济因素的影响。利用欧洲囊性纤维化协会患者登记处(ECFSPR)，获得了全欧洲CF患者的中位生存估计，并研究了社会经济地位对生存的影响。方法包括2010年至2014年间已知存活并在ECFSPR中的CF受试者。使用Kaplan-Meier (KM)方法估计生存曲线。使用对数秩检验评估生存曲线的差异。Cox回归用于评估社会经济因素与年龄特异性死亡危险之间的相关性，并对性别、诊断时年龄、CFTR基因型和移植状态进行了调整。最终分析包括13个国家的31 987名受试者(135 833人年随访)和1435例死亡。ECFSPR中这些患者的中位生存年龄为51.7岁(95% C.I. 50.0-53.4岁)。在对潜在混杂因素(诊断时年龄、性别、CFTR基因型和移植状态)进行调整后，仍有强有力的证据表明社会经济因素与死亡率之间存在关联(p<0.001)。卫生保健支出较高的国家与卫生保健支出最低的国家相比，死亡率风险低46% (HR: 0.54, 95% CI: 0.45-0.64)。解释:欧洲CF患者的中位生存期与其他司法管辖区报道的相当，但因社会经济因素而有所不同。这篇手稿最近已被《欧洲呼吸杂志》接受发表。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. McKone reports grants and personal fees from Vertex Pharmaceutocals, personal fees from Novartis, non-financial support from A Menarini, grants from Gilead, outside the submitted work.Conflict of interest: Dr. Ariti has nothing to disclose.Conflict of interest: Dr. Jackson has nothing to disclose.Conflict of interest: Dr. Zolin has nothing to disclose.Conflict of interest: Dr. Carr reports non-financial support and other from Chiesi Pharmaceuticals, non-financial support and other from Vertex Pharmaceuticals, other from Zambon Pharmaceuticals, other from Insmed, outside the submitted work.Conflict of interest: Dr. Orenti has nothing to disclose.Conflict of interest: Dr. van Rens has nothing to disclose.Conflict of interest: Dr. LEMONNIER has nothing to disclose.Conflict of interest: Dr. Macek has nothing to disclose.Conflict of interest: Dr. Keogh has nothing to disclose.Conflict of interest: Dr. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals. ER -